Biora Therapeutics (BIORQ) AI Stock Analysis

• Market Cap: $452.00
• Dividend Yield: N/A
• Average Volume (3M): 9.55K
• Price to Earnings (P/E): ―
• Beta (1Y): -41.37
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 58
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 4,522,702
• 10 Day Avg. Volume: 3,203
• 30 Day Avg. Volume: 9,551
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 121.18K
• Enterprise Value/Revenue: 31.05
• Enterprise Value/Gross Profit: 38.25
• Enterprise Value/Ebitda: -2.28
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 7 Underperform
• Price Target: ―

Biora Therapeutics has a weak overall score due to severe financial distress, poor technical indicators, and unfavorable valuation metrics. The lack of positive earnings call insights further contributes to the low score, indicating significant risks for investors.

Positive Factors

Revenue Growth

The significant revenue growth indicates a strong potential for market expansion and product adoption, which can drive future profitability and enhance competitive positioning in the biotechnology sector.

Innovative Product Development

Biora's focus on innovative therapies and drug delivery systems positions it well to address unmet medical needs, potentially leading to successful partnerships and licensing opportunities that can drive long-term revenue.

Strategic Partnerships

Strategic partnerships with pharmaceutical companies enhance Biora's market reach and distribution capabilities, providing a durable revenue stream and reducing the risk associated with sole reliance on proprietary products.

Negative Factors

High Leverage

A highly leveraged balance sheet with negative equity increases financial risk, potentially leading to solvency issues and limiting the company's flexibility to navigate market challenges or invest in new opportunities.

Negative Cash Flow

Consistently negative operating cash flows indicate ongoing liquidity pressures, limiting Biora's ability to fund operations and strategic initiatives without external financing, which could strain future growth.

Financial Instability

The company's financial instability, marked by high leverage and negative cash flows, poses a risk to its ability to sustain operations and invest in growth, potentially impacting long-term viability.

Biora Therapeutics Business Overview & Revenue Model

Company Description

Progenity Inc is a biotechnology company. It is engaged in developing and commercializing molecular testing products. The company is translating innovation into precision medicine through diagnostic and therapeutic development platforms based on genomics, proteomics, and microbiomics. The firm generates its revenue from molecular laboratory tests, principally from the sale of Innatal, Preparent, and pathology molecular testing.

How the Company Makes Money

Biora Therapeutics makes money primarily through the development and commercialization of its proprietary drug delivery platforms and therapeutics. The company generates revenue by partnering with other pharmaceutical companies to co-develop products, licensing its technology, and through direct sales of its therapeutics. Significant factors contributing to its earnings include successful clinical trials, regulatory approvals, and strategic partnerships that expand its market reach and enhance distribution capabilities.

Biora Therapeutics Financial Statement Overview

Summary

Biora Therapeutics is facing significant financial challenges, with declining revenue, persistent losses, high leverage, and negative cash flows, indicating financial instability and potential distress.

Income Statement

Biora Therapeutics has shown a significant decline in revenue over the past years, with the latest TTM revenue at $1.76 million compared to $143.99 million in 2019. Gross profit margins are positive in TTM but have fluctuated, suggesting instability in cost management. The company has consistently reported negative EBIT and net income, indicating ongoing operational challenges and lack of profitability.

Balance Sheet

The balance sheet reveals a highly leveraged position with negative stockholders' equity, reflecting financial distress. The company's debt-to-equity ratio is not meaningful due to negative equity. Total liabilities significantly exceed total assets, raising concerns about solvency. The lack of equity cushion and substantial liabilities pose financial risks.

Cash Flow

Operating cash flows are consistently negative, indicating cash burn from operations. Despite occasional positive financing cash flows, free cash flow remains negative, highlighting liquidity pressures. The company struggles to convert net income into cash, as evidenced by negative free cash flow to net income ratios.

Breakdown	TTM	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	1.76M	4.00K	305.00K	1.25M	74.31M	143.99M
Gross Profit	1.43M	4.00K	-602.00K	-190.00K	-19.12M	43.49M
EBITDA	-24.06M	-114.05M	-37.35M	-164.57M	-106.18M	-135.44M
Net Income	-31.54M	-124.11M	-48.83M	-178.52M	-192.53M	-148.04M
Balance Sheet
Total Assets	14.51M	31.21M	53.52M	108.84M	154.44M	101.73M
Cash, Cash Equivalents and Short-Term Investments	3.20M	15.21M	30.49M	88.40M	92.08M	33.04M
Total Debt	39.65M	47.43M	127.81M	126.40M	162.31M	73.37M
Total Liabilities	121.13M	132.64M	155.81M	193.81M	261.43M	185.60M
Stockholders Equity	-106.63M	-101.42M	-102.29M	-84.98M	-106.99M	-83.87M
Cash Flow
Free Cash Flow	-5.50M	-48.60M	-65.21M	-168.34M	-170.69M	-109.85M
Operating Cash Flow	-5.37M	-48.50M	-64.42M	-167.49M	-165.74M	-106.12M
Investing Cash Flow	7.84M	2.44M	-792.00K	-1.24M	-4.94M	16.52M
Financing Cash Flow	31.27M	30.78M	7.30M	165.05M	229.72M	73.64M

Biora Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIORQ, the sentiment is Negative. The current price of 0.12 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.17, and below the 200-day MA of 0.70, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 35.33 is Neutral, neither overbought nor oversold. The STOCH value of 4.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIORQ.

Biora Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNSE	52 Neutral	$14.64M	-0.49	-67.47%	―	―	9.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SABS	50 Neutral	$190.43M	-1.29	-21.16%	―	-92.42%	62.37%
AZTR	45 Neutral	$3.70M	-0.06	-215.04%	―	-100.00%	93.82%
DRMA	44 Neutral	$2.31M	-0.11	-203.36%	―	―	90.53%
GRI	42 Neutral	$3.36M	―	-397.84%	―	―	98.22%
BIORQ	7 Underperform	$452.00	>-0.01	29.58%	―	―	―